Post Herpetic Neuralgia Treatment Market
Post Herpetic Neuralgia Treatment Market Study by Drugs, Patches, and Steroid Injectables through Institutional Sales and Retail Sales from 2024 to 2034
Analysis of Post Herpetic Neuralgia Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Post Herpetic Neuralgia Treatment Market Outlook (2024 to 2034)
Fact.MR’s latest study reveals that the global post herpetic neuralgia treatment market size is forecasted to increase from a value of US$ 822.4 million in 2024 to US$ 1.38 billion by the end of 2034. This amounts to market expansion at a CAGR of 5.3% from 2024 to 2034.
Post-herpetic neuralgia (PHN) is a type of neuropathic pain triggered by an injury. Peripheral nerve damage is frequently caused by the varicella-zoster virus recurrence. The virus is the cause of shingles or herpes zoster. Neuralgia is more prevalent in areas where there is only one sensory nerve. Post-herpetic neuralgia causes pain that can last for up to 85 days. A person may have several different health issues in addition to PHN. Itching, unusual feelings, pain upon light touch, and hyperalgesia are a few examples.
Expansion of the post herpetic neuralgia treatment market size is being driven by large vendors competing for market penetration and distribution. The primary goal of the treatment for post herpetic neuralgia is symptom relief because there is no known cure for the condition.
Key Market Growth Drivers
- Development of new medications generates enormous opportunities for post herpetic neuralgia treatment providers.
- Government support and initiatives for post-herpetic neuralgia treatment worldwide are projected to bolster market growth.
- Increasing global healthcare spending is contributing to the growth of the post-herpetic neuralgia therapy market.
- Manufacturers worldwide are capitalizing on opportunities such as the growing aging population and heightened awareness of post-herpetic neuralgia treatment.
- The market is also being driven by a paradigm shift in public health awareness, supported by advancements in diagnostic tools and increased awareness of risk factors for shingles, facilitating early detection and intervention.
| Report Attributes | Details |
|---|---|
| Post Herpetic Neuralgia Treatment Market Size (2024E) | US$ 822.4 Million |
| Forecasted Market Value (2034F) | US$ 1.38 Billion |
| Global Market Growth Rate (2024 to 2034) | 5.3% CAGR |
| East Asia Market Share (2024E) | 31.1% |
| North America Market Share (2024E) | 35.2% |
| Sales of Post Herpetic Neuralgia Drugs (2024E) | US$ 668.9 Million |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What are the Key Post Herpetic Neuralgia Treatment Market Trends?
“Market Benefiting from Advancements in Healthcare Infrastructure Worldwide”
The market for post herpetic neuralgia treatment is projected to grow steadily due to favorable reimbursement policies and increasing awareness of the benefits of treatment. The global market is also driven by a growing geriatric population and rising prevalence of post-herpetic neuralgia. The expansion of healthcare infrastructure and government support for treatment products are projected to generate lucrative opportunities for treatment providers. Manufacturers are developing novel medications to treat post-herpetic neuralgia, setting trends in the treatment market.
“Incorporation of Digital Healthcare Technologies and Increased Accessibility to Healthcare”
Advancements in biotechnology are significantly contributing to the evolution of precision or personalized medicine, enabling more tailored treatment planning for individual patients based on their genetic composition or unique characteristics. The integration of digital health technologies, including telemedicine, mobile health apps, and remote patient monitoring, is regarded as crucial for enhancing post-herpetic neuralgia management. These innovations hold promise for improving patient outcomes, increasing healthcare accessibility, and generating valuable research data.
What are the Challenges Faced by Post Herpetic Neuralgia Treatment Providers?
“Low Efficacy of Existing PHN Treatment Drugs and Concerns about Side Effects”
The inefficacy and low efficiency of existing post-herpetic neuralgia treatment drugs are projected to hinder post herpetic neuralgia treatment market growth. Limited treatment options further obstruct market expansion. In addition, concerns regarding side effects like dizziness, drowsiness, memory impairment, increased appetite, and weight gain, along with an incomplete understanding of pathophysiology, restrain the market. The financial burden of high treatment costs also impacts patients with post-herpetic neuralgia.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
North America occupies a market share of 35% in 2024. The United States is estimated to hold 86% of the post herpetic neuralgia treatment market share in North America due to the presence of prominent players in the region. China leads the East Asia market, occupying a 50% share. South Korea holds a 30% share of the East Asia market.
How is the Post Herpetic Neuralgia Treatment Market Faring in the United States?
“Rise in PHN Screening Rates and Prevalence of Shingles among Older Adults”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 248 Million |
| Growth Rate (2024 to 2034) | 5.3% CAGR |
| Projected Value (2034F) | US$ 417 Million |
The United States leads the market in North America because of its increased healthcare investments to ensure seamless treatment access. The rise in screening rates for post-herpetic neuralgia treatments, coupled with the growing aging population, is driving market expansion.
- According to the Centers for Disease Control and Prevention (CDC), shingles are increasingly common among older adults in the United States. The CDC estimates that there are 4 to 5 cases of shingles per 1,000 people in the country, and 1 in 3 Americans is projected to experience shingles at some point in their lifetime.
In addition, the presence of major players like Pfizer and Endo Pharmaceuticals is contributing to the expansion of the market in the United States.
How is the Chinese Government Contributing to Market Expansion?
“Government Investments Supporting PHN Management and Prevention”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 129 Million |
| Growth Rate (2024 to 2034) | 5.7% CAGR |
| Projected Value (2034F) | US$ 224 Million |
In major urban areas of China, post-herpetic neuralgia (PHN) imposes a significant financial burden due to both direct medical expenses and indirect costs stemming from lost productivity. It also adversely affects sleep, quality of life, and daily activities, including work performance. These expenses underscore the imperative need for effective PHN management and prevention strategies in the country.
- A study on herpes zoster and its complications in China, as reported by MDPI, revealed an incidence rate of PHN at 0.48 per 1,000 person-years. These factors collectively contribute to the growing sales of post-herpetic neuralgia treatments in China.
Category-wise Insights
The market is primarily categorized into drugs, patches, and steroid injectables, based on type. Drugs are estimated to constitute a leading share of 81% in 2024. In terms of distribution channel, the retail segment accounts for 67% market share in 2024.
Which Treatment Type is Widely Preferred by Healthcare Providers for PHN Management?
“Vital Role of Drugs in Alleviating PHN Pain”
| Attribute | Drugs |
|---|---|
| Segment Value (2024E) | US$ 668.9 Million |
| Growth Rate (2024 to 2034) | 5.4% CAGR |
| Projected Value (2034F) | US$ 1.13 Billion |
Tricyclic antidepressants (TCAs) have analgesic effects even at dosages below what is necessary for their psychological effects. These medications are affordable and essential for treating PHN. In the treatment of Parkinson's disease, gabapentin and pregabalin are first-line antiepileptic medications. They function as calcium channel blockers and aid in PHN pain relief. When it comes to managing pain after treatment, opioids are frequently chosen. They have an impact on brain chemicals that interpret pain signals in the body, like serotonin. Anticonvulsants help calm the nervous system's erratic electrical activity. They work well to reduce pain from PHN and to calm nerve impulses.
How is the Retail Segment Contributing to Increased Sales of Post Herpetic Neuralgia Products?
“Easy Accessibility and Distribution Associated with Retail Sales Channels”
| Attribute | Retail Sales |
|---|---|
| Segment Value (2024E) | US$ 553.2 Million |
| Growth Rate (2024 to 2034) | 5.6% CAGR |
| Projected Value (2034F) | US$ 951.7 Million |
PHN medications are widely accessible through various retail channels, with pharmacies, drugstores, and retail establishments conveniently located for patients. Prescription drugs like TCAs, gabapentin, and pregabalin can be easily obtained from these outlets. This accessibility is particularly convenient for patients experiencing chronic pain. This eliminates the need for patients to visit hospitals to obtain their medications.
Over-the-counter options, including certain PHN topical creams and mild pain relievers, are available in both rural and urban areas. Moreover, retail establishments conduct awareness campaigns to educate patients about PHN and available treatment resources.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Key players in the post herpetic neuralgia treatment market are Pfizer, Arbor Pharma, Assertio Therapeutics, Endo Pharma, Teikoku Pharma, Teva, Mylan, Hengrui Medicine, Acorda Therapeutics, Purdue Pharma L.P., Teikoku Pharma USA, Inc., and Janssen Pharmaceuticals, Inc.
More than half of the revenue share of the global post herpetic neuralgia treatment market is held by Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., and Endo Pharmaceuticals Inc.
- Acasti Pharma announced in July 2022 the commencement of the pharmacokinetic study for GTX-101, its drug candidate for postherpetic neuralgia treatment. GTX-101 is a novel formulation of bupivacaine hydrochloride (HCl) intended for topical administration via a bio-adhesive, film-forming polymer. It aims to alleviate pain associated with postherpetic neuralgia, a neuropathic pain condition resulting from nerve damage caused by the varicella-zoster virus (shingles). The application of bupivacaine hydrochloride (HCl) through the innovative GTX-101 formulation is designed to provide targeted relief when delivered topically via a bioadhesive film-forming polymer.
Segmentation of Post Herpetic Neuralgia Treatment Market Research
-
By Treatment Type :
- Drugs
- Patches
- Steroid Injectables
-
By Distribution Channel :
- Institutional Sales
- Retail Sales
-
By Region :
- North America
- Western Europe
- Eastern Europe
- Latin America
- East Asia
- South Asia & Pacific
- Middle East & Africa
- FAQs -
What is the estimated market size for post herpetic neuralgia treatment in 2024?
The global post herpetic neuralgia treatment market is estimated at 822.4 million in 2024.
What are the projections for the global market for the decade?
The market is forecasted to expand at 5.3% CAGR and reach US$ 1.38 billion by 2034.
What is the forecasted market size for the United States?
Revenue from post herpetic neuralgia treatment in the U.S. is forecasted to reach US$ 248 million in 2024.
What is the valuation of the market in China?
China is estimated to reach a market value of US$ 129 million in 2024.
Which type of treatment accounts for a key share in this market?
Drugs account for 81.3% market share in sales of post herpetic neuralgia treatment.
How is the PHN market faring in Japan?
Japan is projected to reach a market value of US$ 43 million in 2024.
Which distribution channel holds a significant market share?
Retail sales are estimated to account for a market value of US$ 553.2 million in 2024.
Post Herpetic Neuralgia Treatment Market
*Mail attachment includes 104 figures & 72 tables